These findings suggest that WWOX expression may be a useful biomarker in predicting the response to arginine deprivation therapy in HCC patients, particularly when combined with the status of hypoxia and the tissue levels of HIF-1. This evidence concerns the gene HIF1A and hepatocellular carcinoma.